Notice of Zealand's Interim Report for H1 2014 and Related Conference Call

COPENHAGEN, Denmark, Aug. 18, 2014 (GLOBE NEWSWIRE) -- Zealand Pharma A/S ("Zealand") (NASDAQ OMX Copenhagen: ZEAL) will announce its interim report for H1 2014 on Thursday 21 August, in accordance with the company's financial calendar.

Conference Call -- 1400 CET / 0800 EDT on 21 August 2014

On the day of the report, at 1400 CET/ 0800 EDT, Zealand will host a conference call to present the interim results and give an update on the status and outlook for the company's main products, which will be followed by a Q&A session. The call will be hosted by David Solomon, President and CEO, Mats Blom, CFO, and Hanne Leth Hillman, Vice President and Head of R and Corporate Communications.

The conference call will be conducted in English and can be accessed via the following numbers:

DK: + 45 3272 8018
US: + 1 866 6828 490
UK and international: +44 (0) 1452 555 131

A live audio cast of the call including an accompanying slide presentation will be available via the following link:

The audio cast can also be accessed from the investor section of Zealand's website ( and participants are advised to register approximately 10 minutes before the call starts. An on-demand version of the audio cast will also be available on the website following the call.

For further information, please contact:

Hanne Leth Hillman, Vice President and Head of IR & Corporate Communications
Tel: +45 5060 3689, email:

About Zealand Pharma

Zealand Pharma A/S ("Zealand") (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and a mature portfolio of therapeutic products, which are all based on internal inventions. The company's focus lies in the field of cardio-metabolic diseases, diabetes and obesity in particular, and its lead product is lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, marketed as Lyxumia(r) under a license agreement with Sanofi. Lyxumia(r) is approved in several countries globally, including Europe and Japan. In the US, submission of an NDA is expected in 2015, after completion of a cardiovascular outcome study, ELIXA. A once-daily single injection combination of Lyxumia(r) and Lantus(r) (LixiLan) is in Phase III development by Sanofi with planned first regulatory filing as early as at the end of 2015.

Zealand has a partnering strategy for the development and commercialization of its products and in addition to the license agreement with Sanofi in Type 2 diabetes, the company has two collaborations with Boehringer Ingelheim in diabetes/obesity and cardio-metabolic diseases, one with Lilly in diabetes and obesity, one with Helsinn Healthcare in chemotherapy induced diarrhea and a license agreement with AbbVie in acute kidney injury.

For further Follow us on Twitter@ZealandPharma

Source:Zealand Pharma A/S